557 related articles for article (PubMed ID: 26606261)
61. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Gordon ER; Wright CA; James M; Cooper SJ
BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
[TBL] [Abstract][Full Text] [Related]
62. MicroRNA-1285 inhibits malignant biological behaviors of human pancreatic cancer cells by negative regulation of YAP1.
Huang H; Xiong G; Shen P; Cao Z; Zheng L; Zhang T; Zhao Y
Neoplasma; 2017; 64(3):358-366. PubMed ID: 28253715
[TBL] [Abstract][Full Text] [Related]
63. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
Liu F; Liu B; Qian J; Wu G; Li J; Ma Z
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992
[TBL] [Abstract][Full Text] [Related]
64. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
65. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
66. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
67. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine.
Miller AL; Fehling SC; Vance RB; Chen D; Brown EJ; Hossain MI; Heard EO; Andrabi SA; Wang H; Yang ES; Buchsbaum DJ; van Waardenburg RCAM; Bellis SL; Yoon KJ
Cancer Lett; 2024 Jun; 592():216919. PubMed ID: 38704133
[TBL] [Abstract][Full Text] [Related]
68. MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus.
Godfrey JD; Morton JP; Wilczynska A; Sansom OJ; Bushell MD
Cell Death Dis; 2018 May; 9(6):644. PubMed ID: 29844410
[TBL] [Abstract][Full Text] [Related]
69. Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling.
Yang D; Tang Y; Fu H; Xu J; Hu Z; Zhang Y; Cai Q
Biochem Biophys Res Commun; 2018 Oct; 505(1):215-221. PubMed ID: 30243721
[TBL] [Abstract][Full Text] [Related]
70. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
Le Calvé B; Griveau A; Vindrieux D; Maréchal R; Wiel C; Svrcek M; Gout J; Azzi L; Payen L; Cros J; de la Fouchardière C; Dubus P; Guitton J; Bartholin L; Bachet JB; Bernard D
Oncotarget; 2016 May; 7(22):32100-12. PubMed ID: 27050073
[TBL] [Abstract][Full Text] [Related]
71. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
72. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.
Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B
Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125
[TBL] [Abstract][Full Text] [Related]
73. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
[TBL] [Abstract][Full Text] [Related]
74. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
Shen Y; Pan Y; Xu L; Chen L; Liu L; Chen H; Chen Z; Meng Z
Tumour Biol; 2015 Jun; 36(6):4525-34. PubMed ID: 25722110
[TBL] [Abstract][Full Text] [Related]
75. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
Lu Y; Xu D; Peng J; Luo Z; Chen C; Chen Y; Chen H; Zheng M; Yin P; Wang Z
EBioMedicine; 2019 Jun; 44():403-418. PubMed ID: 31103629
[TBL] [Abstract][Full Text] [Related]
76. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
Ohuchida K; Mizumoto K; Kayashima T; Fujita H; Moriyama T; Ohtsuka T; Ueda J; Nagai E; Hashizume M; Tanaka M
Ann Surg Oncol; 2011 Aug; 18(8):2381-7. PubMed ID: 21347785
[TBL] [Abstract][Full Text] [Related]
77. Insulin-like growth factor binding protein 3 chemosensitizes pancreatic ductal adenocarcinoma through its death receptor.
Mofid MR; Gheysarzadeh A; Bakhtiyari S
Pancreatology; 2020 Oct; 20(7):1442-1450. PubMed ID: 32830034
[TBL] [Abstract][Full Text] [Related]
78. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
79. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
80. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]